These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 18629356

  • 1. Update on the use of fibrates: focus on bezafibrate.
    Goldenberg I, Benderly M, Goldbourt U.
    Vasc Health Risk Manag; 2008; 4(1):131-41. PubMed ID: 18629356
    [Abstract] [Full Text] [Related]

  • 2. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Nov 14; 11():140. PubMed ID: 23150952
    [Abstract] [Full Text] [Related]

  • 3. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF, Dimmitt SB.
    Curr Opin Lipidol; 1999 Dec 14; 10(6):561-74. PubMed ID: 10680050
    [Abstract] [Full Text] [Related]

  • 4. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP, Lemieux I, Robins SJ.
    Drugs; 2004 Dec 14; 64(19):2177-98. PubMed ID: 15456334
    [Abstract] [Full Text] [Related]

  • 5. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL, Barradell LB, Plosker GL.
    Drugs; 1996 Nov 14; 52(5):725-53. PubMed ID: 9118820
    [Abstract] [Full Text] [Related]

  • 6. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA.
    Int J Clin Pract; 2011 Jan 14; 65(1):82-101. PubMed ID: 21105969
    [Abstract] [Full Text] [Related]

  • 7. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Jan 14; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

  • 8. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep 14; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 9. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Sep 14; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 10. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A, Motro M, Fisman EZ.
    Cardiovasc Diabetol; 2005 Sep 16; 4():14. PubMed ID: 16168052
    [Abstract] [Full Text] [Related]

  • 11. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M.
    Curr Pharm Des; 2013 Sep 16; 19(17):3124-31. PubMed ID: 23317397
    [Abstract] [Full Text] [Related]

  • 12. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC, Duriez P.
    Drugs Today (Barc); 2006 Jan 16; 42(1):39-64. PubMed ID: 16511610
    [Abstract] [Full Text] [Related]

  • 13. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T, Yagyu H, Itabashi N, Tazoe F, Fujita N, Nagashima S, Okada K, Okazaki M, Furukawa Y, Ishibashi S.
    Hypertens Res; 2008 May 16; 31(5):999-1005. PubMed ID: 18712055
    [Abstract] [Full Text] [Related]

  • 14. Effects of fibrates on serum metabolic parameters.
    Elisaf M.
    Curr Med Res Opin; 2002 May 16; 18(5):269-76. PubMed ID: 12240789
    [Abstract] [Full Text] [Related]

  • 15. Fibric acids: effects on lipids and lipoprotein metabolism.
    Grundy SM, Vega GL.
    Am J Med; 1987 Nov 27; 83(5B):9-20. PubMed ID: 3318457
    [Abstract] [Full Text] [Related]

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 27; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 17. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
    Handelsman Y, Shapiro MD.
    Endocr Pract; 2017 Jan 27; 23(1):100-112. PubMed ID: 27819772
    [Abstract] [Full Text] [Related]

  • 18. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A, de Vries R, van Leeuwen JJ, Gautier T, van Pelt LJ, Tselepis AD, Lagrost L, Dullaart RP.
    Eur J Intern Med; 2012 Oct 27; 23(7):633-8. PubMed ID: 22902096
    [Abstract] [Full Text] [Related]

  • 19. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
    Bezafibrate Infarction Prevention (BIP) studyIsraeli Society for Prevention of Heart Attacks, Tel-Hashomer, Israel. behar@post.tau.ac.il.
    Circulation; 2000 Jul 04; 102(1):21-7. PubMed ID: 10880410
    [Abstract] [Full Text] [Related]

  • 20. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
    Keating GM.
    Am J Cardiovasc Drugs; 2011 Aug 01; 11(4):227-47. PubMed ID: 21675801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.